FDA Balks At Renal Cancer Drug From Aveo, Astellas

Law360, New York (June 10, 2013, 7:46 PM EDT) -- Aveo Pharmaceuticals Inc. on Monday confirmed that the U.S. Food and Drug Administration has refused to approve kidney cancer medicine tivozanib, a failure that follows the termination of more than half the company’s workforce and badly damages a partnership with Astellas Pharma Inc.

The development was expected after an FDA panel last month voted almost unanimously to deny approval, and underscores the precarious financial condition for a company that lacks any approved products and whose shares have entered a tailspin.

According to Aveo, the FDA in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.